InterCure today announced the strategic acquisition of Botanico, also known as ISHI, a medical cannabis technology and brand company. It said the deal delivers immediate access to advanced cultivation technologies and established partnerships with American cannabis operators.
ISHI has a partnership with an indoor facility, AI-driven cultivation optimization systems, automated production capabilities, and partnerships with U.S. cannabis brands, including The Flowery, a vertically integrated medical cannabis company. The Flowery operates cultivation and manufacturing facilities alongside one of the largest delivery systems in Florida's medical market. The Flowery also operates a retail chain in New York.
Through these partnerships, ISHI has developed access to American genetics and cult brands.
"This acquisition represents a significant milestone in our global expansion strategy," said InterCure CEO Alexander Rabinovich. "By acquiring ISHI, we gain immediate access to some of America's most sought-after cannabis genetics and proven operational technologies at exactly the moment when we are encouraged by the reported recent momentum in the U.S. around potential cannabis rescheduling. This acquisition also represents an additional growth engine for InterCure, and we expect it to become accretive to our business model already within the first year. Today, InterCure is uniquely positioned to capitalize on this historic potential regulatory shift and deliver substantial value to our shareholders."
